Comparing new drug combos for advanced head and neck cancer
Part of Cancer clinical trials.
This trial tests whether adding an experimental drug to standard chemotherapy helps people with head and neck cancer that has come back or spread. It aims to see if the combination works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have head and neck cancer (in the mouth, throat, voice box, or nearby areas) that has come back or spread and can't be cured with local treatments.
- You haven't had any previous chemotherapy or other whole-body treatment for this cancer that has come back or spread.
- If you had treatment before, it must have finished more than 6 months ago, except if you had immunotherapy (PD-1/PD-L1) – then it must be at least 12 months since your last dose.
- You must have at least one tumor that can be measured on scans.
- You must be in good enough health (able to do daily activities) – an ECOG score of 0 or 1.
- If you have throat (oropharyngeal) cancer, your doctor must have your HPV test results.
- You cannot have cancer in the nose, sinuses, salivary glands, thyroid, skin, or of unknown origin.
- You must not have had another cancer in the last 3 years, except for certain cured skin or early-stage cancers.
- Your life expectancy must be at least 6 months, and your cancer must not be growing very fast.
- You cannot be pregnant or planning to become pregnant during the trial.
- You must not have a history of serious mental illness or substance abuse that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination treatment, SYS6010 plus enlonstobart, for people with head and neck squamous cell carcinoma that has come back or spread. It aims to see if this combination works better than enlonstobart alone.
This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.
This trial tests adding a targeted therapy (cetuximab) to an immunotherapy (pembrolizumab or finotonlimab) plus chemotherapy for people with head and neck cancer that has spread or come back. The goal is to see if this combination works better than standard treatments.
This trial tests a new drug combination (BL-B01D1 plus a PD-1 inhibitor) for people with advanced head and neck cancer or other solid tumors that have come back or spread. It aims to see if the treatment can help shrink tumors or slow the disease.
This study tests two drugs (pertuzumab and lenvatinib) given together before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve outcomes for patients who haven't received prior cancer treatment.
This trial tests a combination of three drugs (docetaxel, nimotuzumab, and pucotenlimab) for people with head and neck cancer that has come back or spread. It is for those who have already tried and failed treatments like immunotherapy and platinum chemotherapy.
Hear when a new Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.